Johnson & Johnson (NYSE: JNJ) announced today the first clinical data from an ongoing Phase 1b study for JNJ-90014496 (JNJ-4496), an investigational dual-targeting anti-CD19/CD20 bispecific autologous ...

The debate between CAR T-cell therapy and bispecific antibodies is not a rivalry but a question of sequencing, ...

This article explores the current landscape and future potential of cell therapies, including CAR T-cell and stem cell-based ...

Our immune system is designed to protect us by recognizing and attacking infected or abnormal cells. However, cancer cells ...

T-cell therapy has shown remarkable clinical efficacy in haematological malignancies, currently representing a well ...

The study enrolled 18 patients with recurrent GBM who underwent surgery to remove as much of the tumor as possible, followed by infusion of the dual-target CAR-T cell therapy directly into the ...

Six of the patients, of whom four had non-renal SLE, had follow-up of at least 24 weeks. Of those, five showed dramatic ...

Establish Point-of-Care (PoC) CAR-T centers across India using automated manufacturing platforms such as Miltenyi’s CliniMACS Prodigy system, enabling cost-effective and scalable access to ...

AbelZeta Pharma, Inc. ("AbelZeta" or the "Company"), a global clinical-stage biopharmaceutical company focused on discovery and development of innovative and proprietary cell-based therapeutic ...

T cells are a promising cancer therapy that are made from the patient's own T cells, which are reprogrammed to fight their ...

Dr. John Mellors, who heads the cell therapy discovery team for biotechnology company Galapagos, talks about the innovations the organization is making to improve delivery speed and access to CAR ...

During a live event, Konstantinos Sdrimas, MD, and community oncologists discussed patient concerns over CAR T-cell therapy ...